Aardvark to review unblinded ARD-101 data in Q3 2026 amid FDA clinical hold
The company ended its HERO and OLE trials in June 2026 and is reviewing unblinded data while working with the FDA to resolve a hold on ARD-101's IND.
SEC filing
Latest
2 stories